Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2009; 30(01): 1-8
DOI: 10.4103/0971-5851.56328
REVIEW ARTICLE

Tumor markers in clinical practice: General principles and guidelines

S Sharma
Department of Surgical Oncology, Amrita Institute of Medical Sciences & Research Centre, Ernakulam - 682026, Kerala, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Tumor markers are assuming a growing role in all aspects of cancer care, starting from screening to follow-up after treatment, and their judicious application in clinical practice needs a thorough understanding of the basics of pathophysiology, techniques of identification or testing, reasons for out-of-range levels of tumor markers, as well as the knowledge of evidence of their role in any given malignancy. These are, at the most, just an adjunct to diagnosis, and establishing a diagnosis on the basis of tumor markers alone (especially a single result) is fraught with associated pitfalls because of the problem of nonspecificity. In reality an ideal tumor marker does not exist. Detection can be done either in tissue or in body fluids like ascitic or pleural fluid or serum. Clinical uses can be broadly classified into 4 groups: screening and early detection, diagnostic confirmation, prognosis and prediction of therapeutic response and monitoring disease and recurrence. In addition to variable sensitivity and specificity, the prevalence of a particular malignancy may be a major determinant in the application of a particular test as a screening tool. Serum levels, in certain situations, can be used in staging, prognostication or prediction of response to therapy. Monitoring disease is, perhaps, the most common clinical use of serum tumor markers. Rising trend in serum levels may detect recurrence of disease well before any clinical or radiological evidence of disease is apparent ("biochemical recurrence"). Sampling should ideally be repeated after 5-6 half-lives of the marker in question (or the marker with the longest half-life if multiple markers are being considered); but if found elevated, the next sampling after 2-4 weeks, for additional evidence, may be justified.

Keywords

Tumor markers - serum tumor markers - early diagnosis - malignancy


Publication History

Article published online:
19 November 2021

© 2009. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sturgeon C, Hammond E, Chang SL, Sφlιtormos G, Hayes DF. NACB: Practice guidelines and recommendations for use of tumor markers in the clinic: Quality requirements [Section 2]. Draft Guidelines 2006. Available from: http://www.aacc.org/NR/rdonlyres/3CAF1DC0-2E83-4BB1-8517-9300F58DF1DB/0/chp2_qreqs.pdf. [accessed on 2008 Mar 20].
  • 2 Waxman J. Tumor markers. Quart J Med 1995;88:233-41.
  • 3 Gold P, Freeman SO. Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorptions techniques. J Exp Med 1965;121:439-62.
  • 4 Diamandis EP. Tumor markers: Past, present, and future. Tumor markers: Physiology, pathobiology, technology, and clinical applications. In: Diamandis EP, Fritsche H Jr, Lilja H, Chan D, Schwartz M, editors. Washington DC: AACC Press; 2002. p. 3-8.
  • 5 Sokoll LJ, Chan DW. Clinical chemistry: Tumor markers. In Abeloff: Clinical Oncology, 3 rd ed. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, editors. Pennsylvania: Elsevier Churchill Livingston; 2004.
  • 6 Schrohl AS, Anderson MH, Sweep F, Schmitt M, Harbeck N, Foekens J, et al. Tumor markers: From laboratory to clinical utility. Mol Cell Proteomics 2003;2:378-87.
  • 7 Goedegebuure PS, Liyanange U, Eberlein TJ. Tumor biology and tumor markers. In: Townsend: Sabiston textbook of surgery, 17 th ed. In: Townsend CM, Beauchamp RD, Evers BM, Mattox KL, editors. Philadelphia: Elsevier Saunders; 2004.
  • 8 Johnson PJ. A framework for the molecular classification of circulating tumor markers. Ann N Y Acad Sci 2001;945:8-21.
  • 9 Lindblom A, Liljegren A. Tumor markers in malignancies. Br Med J 2000;320:424-7.
  • 10 Cooper DL. Tumor markers. In: Cecil textbook of medicine. In: Goldman, et al., editors. 22 nd ed. Philadelphia: WB Saunders Company; 2004.
  • 11 Wu JT. Diagnosis and management of cancer using serological tumor markers. In: Henry′s Clinical Diagnosis and Management by Laboratory Methods. In: McPherson RA, Pincus MR, editors. 21 st ed. Philadelphia: Elsevier Saunders 2007.
  • 12 Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.
  • 13 Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.
  • 14 Canadian Task Force on the Periodic Health Examination. Canadian Guide to Clinical Preventive Health. Ottawa: Canada Communication Group; 1994. p. 797-809.
  • 15 Cong WM, Wu MC, Zhang XH, Chen H, Yuan JY. Primary hepatocellular carcinoma in women of mainland China: A clinicopathologic analysis of 104 patients. Cancer 1993;71:2941-5.
  • 16 Bast RC Jr, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, et al. Early detection of ovarian cancer: Promise and reality. Cancer Treat Res 2002;107:61-97.
  • 17 Einhorn LH, Lowitz BB. Testicular Cancer. In: Casciato DA, Lowitz BB, editors. Manual of clinical oncology. 3 rd ed. Boston: Little, Brown; 1995. p. 228-36.
  • 18 Testis: TNM classification of malignant tumors. In: Sobin LH, Wittekind C, editor. 5 th ed. New York: Wiley-Liss; 1997. p.174-9.
  • 19 The international non-Hodgkin′s lymphoma prognostic factors project: A predictive model for aggressive non-Hodgkin′s lymphoma. N Engl J Med 1993;329:987-94.
  • 20 Fateh-Moghadam A, Stieber P. Sensible use of tumour markers, 2 nd ed. Marloffstein-Rathsberg: Hartmann Verlag; 1993. p. 11-31.
  • 21 Basuyau JP, Leroy M, Brunelle P. Determination of tumor markers in serum: Pitfalls and good practice. Clin Chem Lab Med 2001;39:1227-33.
  • 22 Fearson ER. Progressing from gene mutations to cancer. In Abeloff: Clinical Oncology, 3 rd ed. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, editors. Pennsylvania: Elsevier Churchill Livingston; 2004.
  • 23 Dalen AV. The basis of tumor marker determinations- Recommendations of the EGTM. Kuwait Med J 2001;33:1-2.
  • 24 Henry NL, Hayes DF . Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 2006;11:541-52.
  • 25 Bigbee W, Herberman RB. Tumor markers and immunodiagnosis. In: Bast RC Jr, Kufe DW, Pollock RE, et al., editors. Cancer Medicine. 6 th ed. Hamilton, Ontario, Canada: BC Decker Inc.; 2003.
  • 26 Sturgeon C, Aronsson AC, Duffy MJ, Hansson LO, Klapdor R, Dalen A van. European group on tumour markers: Consensus recommendations. Anticancer Res 1999;19:2789.
  • 27 Recommendations of European Group on Tumor Markers (EGTM). Anticancer Res 1999;19(4A):2791-819.
  • 28 Lee P, Pincus MR, McPherson RA. Diagnosis and management of Cancer using serological tumor markers. In: Henry′s clinical diagnosis and management by laboratory methods. In: McPherson RA, Pincus MR, editors. 21 st ed. Philadelphia: Elsevier Saunders; 2007. p. 1353-66.
  • 29 Wu JT, Nakmura R. Human circulating tumor markers. Chicago: American Association of Clinical Pathologist; 1997.
  • 30 Wu JT, Christensen SE. Effect of different test designs of immunoassays on ′′hook effect′′ of CA 19-9 measurement. J Clin Lab Anal 1991;5:228.
  • 31 Wu JT, Knight JA. Monoclonal immunoassays for tumor markers. Clin Chem 1988;28:1.
  • 32 Bast RC Jr, Knauf S, Epenetos A, Dhokia B, Daly L, Tanner M, et al. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer 1991;68:1758.
  • 33 Wu JT. Expression of monoclonal antibody defined tumor markers in four carcinomas. Ann Clin Lab Sci 1989;19:17.
  • 34 Katopodis N. Lipid associated sialic acid test for the detection of human cancer. Cancer Res 1982;42:5270.
  • 35 Nahm MH, Hoffmann JW: Heteroantibody: Phantom of the immunoassay. Clin Chem 1990;36:829.
  • 36 Sturgeon C. Practice Guidelines for tumor marker use in the clinic. Clin Chem 2002;48:1151-9.
  • 37 Fleisher M, Dnistrian AM, Sturgeon CM, Lamerz R, Whittliff Jl. Practice guidelines and recommendations for use of tumor markers in the clinic. In Tumor markers: Physiology, pathobiology, technology, and clinical applications. In: Diamandis EP, Fritsche H Jr, Lilja H, Chan D, Schwartz M, editors. Washington, DC: AACC Press; 2002.
  • 38 Bonfrer JM. Working group on Tumor marker criteria. Tumor Biol 1990;11:287-8.